IE920979A1 - Pyridazinone acetic acids - Google Patents

Pyridazinone acetic acids

Info

Publication number
IE920979A1
IE920979A1 IE097992A IE920979A IE920979A1 IE 920979 A1 IE920979 A1 IE 920979A1 IE 097992 A IE097992 A IE 097992A IE 920979 A IE920979 A IE 920979A IE 920979 A1 IE920979 A1 IE 920979A1
Authority
IE
Ireland
Prior art keywords
methyl
compound
oxo
dihydro
formula
Prior art date
Application number
IE097992A
Other languages
English (en)
Inventor
Banavara L Mylari
William James Zembrowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IE920979A1 publication Critical patent/IE920979A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IE097992A 1991-03-28 1992-03-27 Pyridazinone acetic acids IE920979A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
IE920979A1 true IE920979A1 (en) 1992-10-07

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
IE097992A IE920979A1 (en) 1991-03-28 1992-03-27 Pyridazinone acetic acids

Country Status (19)

Country Link
EP (1) EP0582643A1 (enExample)
JP (1) JPH06500793A (enExample)
CN (1) CN1065269A (enExample)
AU (1) AU658887B2 (enExample)
BR (1) BR9205810A (enExample)
CA (1) CA2107104A1 (enExample)
CZ (1) CZ387092A3 (enExample)
DE (1) DE9290035U1 (enExample)
FI (1) FI934222L (enExample)
HU (1) HUT67836A (enExample)
IE (1) IE920979A1 (enExample)
IL (1) IL101325A0 (enExample)
MX (1) MX9201414A (enExample)
NZ (1) NZ242152A (enExample)
PT (1) PT100301A (enExample)
TW (1) TW207998B (enExample)
WO (1) WO1992017446A2 (enExample)
YU (1) YU30392A (enExample)
ZA (1) ZA922238B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
YU71403A (sh) 2001-03-30 2006-05-25 Pfizer Products Inc. Piridazinoni kao inhibitori aldoza reduktaze
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (zh) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase

Also Published As

Publication number Publication date
IL101325A0 (en) 1992-11-15
PT100301A (pt) 1993-06-30
HU9302728D0 (en) 1993-12-28
ZA922238B (en) 1993-09-27
FI934222A0 (fi) 1993-09-27
AU658887B2 (en) 1995-05-04
CA2107104A1 (en) 1992-09-29
MX9201414A (es) 1992-10-01
BR9205810A (pt) 1994-06-28
YU30392A (sh) 1994-11-15
DE9290035U1 (de) 1993-11-18
CN1065269A (zh) 1992-10-14
FI934222A7 (fi) 1993-09-27
WO1992017446A3 (en) 1992-11-26
JPH06500793A (ja) 1994-01-27
TW207998B (enExample) 1993-06-21
WO1992017446A2 (en) 1992-10-15
AU1779692A (en) 1992-11-02
CZ387092A3 (en) 1994-02-16
FI934222L (fi) 1993-09-27
EP0582643A1 (en) 1994-02-16
NZ242152A (en) 1994-07-26
HUT67836A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
EP0222576B1 (en) Heterocyclic oxophthalazinyl acetic acids
AU734218B2 (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US5268386A (en) Certain 3,4-dihydro 4-oxospiro [2H-1 benzopyrans] useful for treating hyperuricemia
HU215450B (hu) Eljárás 2,4-dioxo-tiazolidin-származékok előállítására
AU611610B2 (en) Pyridazinone derivatives
EP0436307B1 (en) Substituted oxophthalazinyl acetic acids and analogs thereof
US5338855A (en) Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses
IE920979A1 (en) Pyridazinone acetic acids
JPH0536436B2 (enExample)
DE69625795T2 (de) Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
EP0553130B1 (en) Pyrrolidine dione derivatives
EP0136143B1 (en) Spiro-succinimides for treatment of diabetes complications
US4843062A (en) N-acyl-N-napthoylglycines as aldose reductase inhibitors
US4457939A (en) Aldose reductase inhibiting 5-(2-alkoxy-3-substituted phenyl)hydantoins
KR860001507B1 (ko) 5-(치환된 페닐) 히단토인의 제조방법
HU211128A9 (en) Substituted isoxazole and isothiazole derivatives
US4766141A (en) Spiro-succinimides for treatment of diabetes complications
EP0112620B1 (en) 5-(substituted phenyl) hydantoins
DE19711617A1 (de) Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CA1188318A (en) N-(substituted-naphthoyl)glycine derivatives
EP0568540A1 (en) 2,4-DIOXO-PYRIDO 2,3-d]PYRIMIDINE-3-ACETIC ACIDS AND ESTERS AND SALTS THEREOF
HU198212B (en) Process for production of spiro-imidasolones
JPWO1996020186A1 (ja) カルボン酸誘導体、その製造方法及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
FA9A Application withdrawn section 33(1)